HLHoward M. Loree

Howard M. Loree

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Howard M. Loree has a total of 14 co-authors. Here are the top co-authors by number of shared publications:

  • Andreas Fleischli

    Sulzer Markets and Technology, (now Levitronix GmbH), Zürich, Switzerland; and

    1 shared publication
  • David B. Gernes

    Research Dept., Thermo Cardiosystems Inc. (now Thoratec Corp.), Woburn, Massachusetts, U.S.A.

    1 shared publication
  • Giampiero Foiera

    Sulzer Markets and Technology, (now Levitronix GmbH), Zürich, Switzerland; and

    1 shared publication
  • J. Scott Richardson

    Research Dept., Thermo Cardiosystems Inc. (now Thoratec Corp.), Woburn, Massachusetts, U.S.A.

    1 shared publication
  • Kenneth N. Litwak

    McGowan Center for Artificial Organ Development, University of Pittsburgh, Pittsburgh, Pennsylvania, U.S.A.

    1 shared publication
  • Kevin Bourque

    Research Dept., Thermo Cardiosystems Inc. (now Thoratec Corp.), Woburn, Massachusetts, U.S.A.

    1 shared publication

Latest Publications

  • The HeartMate III: Design and In Vivo Studies of a Maglev Centrifugal Left Ventricular Assist Device

    by Howard M. Loree, Kevin Bourque, David B. Gernes, J. Scott Richardson, Victor L. Poirier, Natale Barletta, Andreas Fleischli, Giampiero Foiera, Thomas M. Gempp, Reto Schoeb, et al.

    A compact implantable centrifugal left ventricular assist device (LVAD) (HeartMate III) featuring a magnetically levitated impeller is under development. The goal of our ongoing work is to demonstrate feasibility, low hemolysis, and low thrombogenicity of the titanium pump in chronic bovine in vivo studies. The LVAD is based on so‐called bearingless motor technology and combines pump rotor, drive, and magnetic bearing functions in a single unit. The impeller is rotated (θz) and levitated with both active (X, Y) and passive (Z, θx, θy) suspension. Six prototype systems have been built featuring an implantable titanium pump (69 mm diameter, 30 mm height) with textured blood contacting surfaces and extracorporeal electronics. The pumps were implanted in 9 calves (≤100 kg at implant) that were anticoagulated with Coumadin (2.5 ≤ INR ≤ 4.0) throughout the studies. Six studies were electively terminated (at 27–61 days), 1 study was terminated after the development of severe pneumonia and lung atelectasis (at 27 days) another study was terminated after cardiac arrest (at 2 days) while a final study is ongoing (at ≈100 days). Mean pump flows ranged from 2 to 7 L/min, except for brief periods of exercise at 6 to 9 L/min. Plasma free hemoglobin ranged from 4 to 10 mg/dl. All measured biochemical indicators of end organ function remained within normal range. The pumps have met performance requirements in all 9 implants with acceptable hemolysis and no mechanical failures.